New FDA guidance could spur biomarker-guided clinical trials

FDA released draft guidance on Tuesday providing an evidentiary framework for biomarker qualification, which could encourage developers to submit biomarkers for qualification and expand opportunities for biomarker-guided clinical trials.

Qualified biomarkers can be used across multiple

Read the full 356 word article

User Sign In